Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
23 March 2016Website:
http://www.corvuspharma.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:28:33 GMTDividend
Analysts recommendations
Institutional Ownership
CRVS Latest News
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) held its Q1 2024 Earnings Conference Call on May 6, 2024 at 4:30 PM ET. Participants included Zack Kubow from Real Chemistry, Richard Miller (President and CEO, Co-Founder), Leiv Lea (Chief Financial Officer), Jeffrey Arcara (Chief Business Officer), James Rosenbaum (Senior Vice President of Research), and Ben Jones (Senior Vice President of Regulatory and Pharmaceutical Sciences). Conference call participants included Jeff Jones from Oppenheimer, Graig Suvannavejh from Mizuho Securities, Liang Cheng from Jefferies, and Rosemary Li from Cantor Fitzgerald. The call provided a business update and reported on the company's financial results for the first quarter of 2024. All lines were in a listen-only mode during the call.
The selling pressure for Corvus (CRVS) may have decreased as it is now considered oversold. Along with this technical indicator, the consensus among analysts on Wall Street raising earnings estimates suggests the stock is ready for a turnaround.
Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company?
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What type of business is Corvus Pharmaceuticals?
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
What sector is Corvus Pharmaceuticals in?
Corvus Pharmaceuticals is in the Healthcare sector
What industry is Corvus Pharmaceuticals in?
Corvus Pharmaceuticals is in the Biotechnology industry
What country is Corvus Pharmaceuticals from?
Corvus Pharmaceuticals is headquartered in United States
When did Corvus Pharmaceuticals go public?
Corvus Pharmaceuticals initial public offering (IPO) was on 23 March 2016
What is Corvus Pharmaceuticals website?
https://www.corvuspharma.com
Is Corvus Pharmaceuticals in the S&P 500?
No, Corvus Pharmaceuticals is not included in the S&P 500 index
Is Corvus Pharmaceuticals in the NASDAQ 100?
No, Corvus Pharmaceuticals is not included in the NASDAQ 100 index
Is Corvus Pharmaceuticals in the Dow Jones?
No, Corvus Pharmaceuticals is not included in the Dow Jones index
When was Corvus Pharmaceuticals the previous earnings report?
No data
When does Corvus Pharmaceuticals earnings report?
The next expected earnings date for Corvus Pharmaceuticals is 07 November 2024